{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:50:56Z","timestamp":1792702256246,"version":"4.5.0"},"reference-count":25,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction and Objective:<\/jats:title>\n                    <jats:p>Most patients with type 1 diabetes (T1D) in the United States are overweight (OW) or obese (OB), contributing to insulin resistance and suboptimal glucose control. The primary Food and Drug Administration-approved treatment for T1D is insulin, which may adversely affect weight. Tirzepatide is approved for managing type 2 diabetes, improves glucose control, facilitates weight loss, and improves cardiovascular disease outcomes. We assessed the use of tirzepatide in OW\/OB subjects with T1D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a retrospective single-center real-world study in 62 OW\/OB adult patients with T1D who were prescribed tirzepatide (treated group) and followed for 1 year. At least 3 months of use of tirzepatide was one of the inclusion criteria. Based on the inclusion criteria, this study represents 62 patients out of 184 prescribed tirzepatide. The control group included 37 OW\/OB patients with T1D (computer frequency matched by age, duration of diabetes, gender, body mass index (BMI), and glucose control) who were not using any other weight-loss medications during the same period. The mean (\u00b1standard deviation [SD]) dose of weekly tirzepatide at 3 months was 5.6\u2009\u00b1\u20091.9\u2009mg that increased to 9.7\u2009\u00b1\u20093.3\u2009mg at 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The gender, mean baseline age, duration of diabetes, and glycosylated hemoglobin (HbA1c) were similar in the two groups, whereas BMI and weight were higher in the treated group. There were significantly larger declines in BMI and weight in the treated group than in controls across all time points among those in whom data were available. HbA1c decreased in the treated group as early as 3 months and was sustained through a 1-year follow-up (\u22120.67% at 1 year). As expected, insulin dose decreased at 3 months and throughout the study period. There were no reported hospitalizations from severe hypoglycemia or diabetic ketoacidosis. The mean glucose, time-in-range, time-above-range, SD, and coefficient of variation (continuous glucose monitoring metrics) significantly improved in the treated group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this pilot (off label) study, we conclude that tirzepatide facilitated an average 18.5% weight loss (&gt;46 pounds) and improved glucose control in OW\/OB patients with T1D at 1 year. For safe use of tirzepatide in patients with T1D, we strongly recommend a large prospective randomized control trial in OW\/OB patients with T1D.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/dia.2024.0050","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T11:52:45Z","timestamp":1711021965000},"page":"367-374","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":63,"title":["Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes"],"prefix":"10.1177","volume":"26","author":[{"given":"Satish K.","family":"Garg","sequence":"first","affiliation":[{"name":"Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4518-5179","authenticated-orcid":false,"given":"Halis K.","family":"Akturk","sequence":"additional","affiliation":[{"name":"Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurleen","family":"Kaur","sequence":"additional","affiliation":[{"name":"Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie","family":"Beatson","sequence":"additional","affiliation":[{"name":"Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Snell-Bergeon","sequence":"additional","affiliation":[{"name":"Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291401"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1990"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470"},{"key":"e_1_3_5_5_2","unstructured":"Garg SK Rodriguez E Almurashi AM. Continuous Glucose Monitors\/Hybrid Closed Loop Systems. Medscape; 2022. Available from: https:\/\/emedicine.medscape.com\/article\/2500145-overview"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2023.0467"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2022.0421"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2022.0421"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0384"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2023.0320"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2023.0490"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S008"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708337"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.15858"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-0042"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1165471"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2024.0023"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2023.0389"},{"key":"e_1_3_5_22_2","unstructured":"Abbott Announcement for Continuous Ketone Monitor Availability in 2024: ADA Scientific Sessions New Orleans 2022. Close Concerns June; 2022."},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19574"},{"key":"e_1_3_5_24_2","unstructured":"GLP-1 Drug Zepbound (Tirzepatide) Explained: New Obesity Treatment Approved by FDA: Nov 2023; FDA.Gov [Last accessed: January 12 2024]."},{"key":"e_1_3_5_25_2","article-title":"Obesity drugs lead to muscle loss\u2014Pharma companies want to fix that","author":"Wainer D.","unstructured":"Wainer D. Obesity drugs lead to muscle loss\u2014Pharma companies want to fix that. Wall Street J Jan 22nd, 2024. [Last accessed: March 15, 2024].","journal-title":"Wall Street J"},{"key":"e_1_3_5_26_2","unstructured":"Olsen B. A weight-loss drug changed my life. Will it solve my problem? Wall Street J Jan 12 2024. [Last accessed: March 14 2024]."}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2024.0050","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2024.0050","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2024.0050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:14:37Z","timestamp":1777400077000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2024.0050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1089\/dia.2024.0050"],"URL":"https:\/\/doi.org\/10.1089\/dia.2024.0050","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}